JP2012525358A5 - - Google Patents

Download PDF

Info

Publication number
JP2012525358A5
JP2012525358A5 JP2012507765A JP2012507765A JP2012525358A5 JP 2012525358 A5 JP2012525358 A5 JP 2012525358A5 JP 2012507765 A JP2012507765 A JP 2012507765A JP 2012507765 A JP2012507765 A JP 2012507765A JP 2012525358 A5 JP2012525358 A5 JP 2012525358A5
Authority
JP
Japan
Prior art keywords
treatment
medicament
allopurinol
induced
hfsr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012507765A
Other languages
English (en)
Japanese (ja)
Other versions
JP6007101B2 (ja
JP2012525358A (ja
Filing date
Publication date
Priority claimed from EP09382058A external-priority patent/EP2246057A1/en
Application filed filed Critical
Publication of JP2012525358A publication Critical patent/JP2012525358A/ja
Publication of JP2012525358A5 publication Critical patent/JP2012525358A5/ja
Application granted granted Critical
Publication of JP6007101B2 publication Critical patent/JP6007101B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012507765A 2009-04-29 2010-04-29 手足皮膚反応治療のためのアロプリノールの使用 Expired - Fee Related JP6007101B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US21489409P 2009-04-29 2009-04-29
US61/214,894 2009-04-29
EP09382058A EP2246057A1 (en) 2009-04-29 2009-04-29 Use of allopurinol for the treatment of hand foot skin reaction
EP09382058.7 2009-04-29
PCT/EP2010/055806 WO2010125143A1 (en) 2009-04-29 2010-04-29 Use of allopurinol for the treatment of hand foot skin reaction

Publications (3)

Publication Number Publication Date
JP2012525358A JP2012525358A (ja) 2012-10-22
JP2012525358A5 true JP2012525358A5 (enExample) 2014-12-11
JP6007101B2 JP6007101B2 (ja) 2016-10-12

Family

ID=40897536

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012507765A Expired - Fee Related JP6007101B2 (ja) 2009-04-29 2010-04-29 手足皮膚反応治療のためのアロプリノールの使用

Country Status (22)

Country Link
US (2) US8623878B2 (enExample)
EP (2) EP2246057A1 (enExample)
JP (1) JP6007101B2 (enExample)
KR (1) KR20120049848A (enExample)
CN (1) CN102421436B (enExample)
AR (1) AR076505A1 (enExample)
AU (2) AU2010243594A1 (enExample)
BR (1) BRPI1011971A2 (enExample)
CA (1) CA2759085C (enExample)
DK (1) DK2424538T3 (enExample)
ES (1) ES2434366T3 (enExample)
HR (1) HRP20131070T1 (enExample)
IL (1) IL215831A (enExample)
ME (1) ME01567B (enExample)
MX (1) MX2011011529A (enExample)
NZ (1) NZ595901A (enExample)
PL (1) PL2424538T3 (enExample)
PT (1) PT2424538E (enExample)
RS (1) RS53005B (enExample)
RU (1) RU2543325C2 (enExample)
SI (1) SI2424538T1 (enExample)
WO (1) WO2010125143A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010306671B2 (en) 2009-10-16 2015-12-17 Duke University Compositions and methods for the treatment of drug-induced hand-foot syndrome
CA2824933A1 (en) * 2011-01-18 2012-07-26 Vicus Therapeutics, Llc Pharmaceutical compositions and methods for making and using them
CA3085013A1 (en) 2017-12-13 2019-06-20 Onquality Pharmaceuticals China Ltd. A method for preventing or treating egfr-inhibition associated diseases
CN113975264A (zh) * 2018-04-16 2022-01-28 上海岸阔医药科技有限公司 预防或治疗肿瘤疗法副作用的方法
US20200046703A1 (en) * 2018-08-09 2020-02-13 Asymmetric Therapeutics, Llc Compositions and methods for treatment of the side-effects associated with administration of therapeutic agents
US20250114362A1 (en) 2022-01-05 2025-04-10 Asymmetric Therapeutics, Llc Methods and compositions for treatment of cutaneous proliferative disorders and other skin conditions
KR20250056445A (ko) * 2023-10-19 2025-04-28 (주) 수파드엘릭사 수족증후군 또는 수족피부반응의 예방 또는 치료용 약학 조성물

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3772193D1 (de) * 1987-02-13 1991-09-19 Allergan Pharma Verwendung von pteridinen und/oder purinen oder eines xanthinoxidase-hemmers zur herstellung eines arzneimittels zur behandlung von genetisch bedingten degenerativen netzhauterkrankungen.
AU4974893A (en) 1992-09-04 1994-03-29 Aws Shakir Mustafa Salim Skin treatment compositions containing dimethylsulphone and allopurinol or oxypurinol
GB9218711D0 (en) 1992-09-04 1992-10-21 Salim Aws S M Skin cancer treatment
JP3106817B2 (ja) 1993-11-02 2000-11-06 富士電機株式会社 漏電遮断器
US6284234B1 (en) * 1998-08-04 2001-09-04 Johnson & Johnson Consumer Companies, Inc. Topical delivery systems for active agents
US6060083A (en) * 1999-04-01 2000-05-09 Topical Technologies, Inc. Topical DMSO treatment for palmar-plantar erythrodysethesia
GB0013346D0 (en) * 2000-06-01 2000-07-26 Glaxo Group Ltd Therapeutic benzamide derivatives
JP4822652B2 (ja) * 2000-11-22 2011-11-24 エンド ファーマシューティカルズ インコーポレイテッド 粘膜炎の治療
US7544348B2 (en) * 2001-02-15 2009-06-09 Access Pharmaceuticals, Inc. Liquid formulations for the prevention and treatment of mucosal diseases and disorders
SE0100873D0 (sv) * 2001-03-13 2001-03-13 Astrazeneca Ab Method of treatment
DK1455888T3 (da) 2001-08-29 2009-08-24 Pharmakodex Ltd Topisk indgivelsesindretning
US20030157191A1 (en) * 2001-11-29 2003-08-21 Sound Pharmaceuticals Incorporated Methods and compositions for ameliorating the undesirable effects of chemotherapy
DE10200578A1 (de) 2002-01-09 2003-07-10 Roehm Gmbh Haft- und Bindemittel für dermale oder transdermale Therapiesysteme
US6979688B2 (en) * 2002-02-12 2005-12-27 Ford John P Treatment method against side-effects of chemotherapy
US20040214215A1 (en) 2003-03-07 2004-10-28 Yu Ruey J. Bioavailability and improved delivery of alkaline pharmaceutical drugs
WO2004110380A2 (en) 2003-06-11 2004-12-23 Novacea, Inc. Treatment of immune-mediated disorders with active vitamin d compounds alone or in combination with other therapeutic agents
CA2528359A1 (en) * 2003-06-11 2004-12-23 Novacea, Inc. Treatment of cancer with active vitamin d compounds in combination with radiotherapeutic agents and treatments
US20050148907A1 (en) * 2003-12-24 2005-07-07 Gregory Skover Treatment of skin using a benefit agent and an apparatus
JP4405326B2 (ja) 2004-06-28 2010-01-27 株式会社東芝 ランドリー機器
ES2312012T3 (es) 2004-09-17 2009-02-16 Biomas Ltd. Nuevos compuestos de telurio y su uso como inmunomodulares.
HRP20100210T1 (hr) 2006-06-01 2010-05-31 Nobera Pharma Upotreba alopurinola u liječenju eritrodisestezije dlana i stopala

Similar Documents

Publication Publication Date Title
JP2014515373A5 (enExample)
JP2014516942A5 (enExample)
JP2013516482A5 (enExample)
JP2015528471A5 (enExample)
CA2883751A1 (en) Methods of treating alzheimer's disease and pharmaceutical compositions thereof
NZ714963A (en) Compositions and methods for treating anemia
RU2008152341A (ru) Применение аллопуринола для лечения ладонно-подошвенной эритродизестезии
JP2017506624A5 (enExample)
RU2012133969A (ru) Локальные трансдермальные композиции дексмедетомидина и способы их применения
JP2013511534A5 (enExample)
JP2002528502A5 (enExample)
JP2017533972A5 (enExample)
JP2013541583A5 (enExample)
RU2015102772A (ru) Бензодиазелипы для мелкоклеточного рака легкого
JP2019515909A5 (enExample)
JP2023522415A5 (enExample)
JP2020500864A5 (enExample)
JP2018517759A5 (enExample)
CA2313270A1 (en) Use of deferiprone in treating and preventing iron-induced cardiac disease
JP2016505050A5 (enExample)
RU2013108390A (ru) Фармацевтическая композиция для предотвращения периоперационной артериальной гипотензии у человека
RU2011148355A (ru) Применение аллопуринола для ладонно-родошвенного синдрома
JP2011500589A5 (enExample)
JP2022512158A5 (enExample)
CN110755432A (zh) 烟酰胺在制备治疗手足皮肤反应制剂中的应用